TD Cowen Maintains AstraZeneca(AZN.US) With Buy Rating, Announces Target Price $95

Moomoo News00:33 ET · Ratings

TD Cowen Keeps Their Buy Rating on AstraZeneca (AZN)

TipRanks00:15 ET · Ratings

AstraZeneca (AZN.US) and MSD (MRK.US) announce long-term results from phase 3 Olympia clinical trial

Lynparza is a “first-in-class” PARP inhibitor and the first synthetic lethal targeted therapy to target cells/tumors with homologous recombinant repair (HRR) defects (such as cells carrying BRCA1 and/or BRCA2 mutations).

Zhitong Finance18:56 ET

AstraZeneca, Merck Report Positive Long-term Data for Lynparza

Seeking Alpha14:04 ET

AstraZeneca Says 87.5% of Lynparza-treated Patients Alive at Six Years in Trial

TipRanksDec 11 10:25 ET

Express News | Lynparza Shows Significant Survival Benefit In Early Breast Cancer In OlympiA Phase III Trial; Reduces Risk Of Death By 28% And Recurrence By 35% At Six Years, Becoming First PARP Inhibitor To Improve Survival In Early Breast Cancer

BenzingaDec 11 10:16 ET